Developing the next generation of cancer diagnostics - objective, accurate, and delivers results in real-time, helping extend screening programmes globally
Zilico is developing the next generation of diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-time. These characteristics allow for the improvement of clinical screening programmes, globally. The product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) platform technology. EIS is a scientifically-proven method to differentiate between normal, pre cancerous and cancerous tissues.